Introduction to nebivolol hydrochloride (Bystolic) and summary of global listings

Nebivolol hydrochloride (Nebivolol), trade name Bystolic, is a third-generation selective β1 receptor blocker that has dual functions of heart rate control and vasodilation. The drug improves vascular endothelial function by enhancing the release of carbon monoxide (NO), while maintaining a good inhibitory effect on the heart, so it has less impact on metabolism while lowering blood pressure. BystolicIt is mainly used to treat essential hypertension and is also used in the management of chronic heart failure in some countries. It is especially suitable for the elderly or patients with metabolic abnormalities.

Bystolic was developed by the German Merck KGaA company. It was first approved for marketing in Europe in 2001 and was subsequently widely used in France, Germany, Italy, Belgium and other countries. In 2007, the U.S.FDA approved it for the treatment of hypertension. It was introduced to the U.S. market by Forest Laboratories and later taken over by Allergan. In North America and Europe, Bystolic has become one of the beta blockers recommended in many guidelines due to its good tolerability and clinical efficacy.

AlthoughBystolic has been successfully marketed in many countries around the world, the drug has not yet been officially approved for marketing in mainland China. There is no original Bystolic for sale in the domestic market. If patients want to use the drug, they usually need to obtain it through overseas channels. In addition, although some domestic pharmaceutical companies have launched other types of beta-blockers, generic drugs containing Nebivolol ingredients are not yet widely marketed or circulated.

Overall, Bystolic has been widely recognized in the international field of hypertension treatment due to its unique pharmacological mechanism and good efficacy. As global medical demand increases, the drug is expected to gradually enter the market in more countries in the future, benefiting more patients in need of precise blood pressure reduction and cardiovascular protection. The formal introduction into the Chinese market still requires further approval and policy promotion.

Reference materials:https://www.drugs.com/